CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News UpdateUNITED STATES: FDA Fast Tracks AbbVie Hepatitis C Drug
May 8, 2013
According to AbbVie, the Food and Drug Administration (FDA) has given its new hepatitis C drug regimen a breakthrough therapy designation, which will speed up its potential approval in the United States. The FDA’s designation stems from clinical trial results, which have shown a high response rate to the combination therapy in which patients receive 12–24 weeks of treatment with nearly one year of post-treatment follow-up.
Read Full Article